Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-27 @ 11:04 PM
Study NCT ID:
NCT04957160
Status:
COMPLETED
Last Update Posted:
2024-12-17
First Post:
2021-01-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
Sponsor:
Ipsen
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Renal Cell Carcinoma (aRCC) | View |
Keywords: